Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Revenue of Beyond Air, Inc. (XAIR)
Revenue in 2024 (TTM): $1.16 M
According to Beyond Air, Inc.'s latest financial reports the company's current revenue (TTM) is $1.16 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Beyond Air, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2024 | $1.16 M | $-1,307,000 | $-60,655,000 | $-64,295,000 | $-60,242,000 |
| 2023 | $ | $-555,000 | $-50,889,000 | $-59,401,000 | $-55,816,000 |
| 2022 | $ | $-588,000 | $-29,622,000 | $-44,060,000 | $-43,177,000 |
| 2021 | $873 K | $873 K | $-22,002,000 | $-22,875,000 | $-22,875,000 |
| 2020 | $1.39 M | $1.39 M | $-17,982,532 | $-20,096,804 | $-19,942,504 |
| 2019 | $7.72 M | $7.72 M | $-2,996,792 | $-6,558,450 | $-6,558,450 |
| 2018 | $ | $-38,000 | $-16,946,000 | $-18,044,000 | $-18,044,000 |
| 2017 | $ | $ | $-3,382,000 | $-3,693,000 | $-3,720,000 |
| 2016 | $ | $ | $-29,286 | $-29,748 | $-29,748 |
| 2015 | $ | $ | $-2,136,000 | $-4,622,000 | $-4,807,000 |
| 2014 | $ | $ | $-1,369,000 | $-1,574,000 | $-1,645,000 |